Filing Flows › Ultragenyx Pharmaceutical (RARE) › Q1 2025
Ultragenyx Pharmaceutical (RARE) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 7, 2025
Ultragenyx Pharmaceutical (RARE) reported revenue of $139M for the first quarter 2025 (Q1 2025), +28% from a year earlier and -16% from the quarter before. Operating margin was -102.9%, net loss $151M (108.6% of revenue).
Ultragenyx Pharmaceutical, Q1 2025: revenue $139M (+28% year over year), operating margin -102.9%, net loss $151M, operating cash flow −$166M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $139M | -16% | +28% |
| Operating profit | −$143M | — | — |
| Net earnings | −$151M | — | — |
| Operating cash flow | −$166M | — | — |
What changed
Revenue was $139.0M in Q1 2025, up 28% year over year and down 16% from the previous quarter. Product was the largest line at 66% of revenue. Product added $29.0M year over year (up 46%), 96% of the total change.
Operating costs exceeded revenue by $143.0M, an operating margin of -102.9%. Total costs grew 3% against revenue growth of 28%. The fastest-growing cost line was Other operating costs (+65%). The quarter ended with a net loss of $151.0M, wider than the previous quarter's $133.2M loss.
Operating cash flow was −$166.0M. Non-cash charges added back $9.0M of depreciation and amortization and $40K of share-based compensation. Working capital and other items used $24.0M. Capital expenditures of $1.3M exceeded it, leaving free cash flow of −$167.3M.
Questions
What was Ultragenyx Pharmaceutical's revenue in the first quarter 2025?
Ultragenyx Pharmaceutical (RARE) reported revenue of $139M for the first quarter 2025 (Q1 2025), +28% from a year earlier and -16% from the quarter before.
Was Ultragenyx Pharmaceutical profitable in the first quarter 2025?
Operating loss was $143M (-102.9% of revenue) and net loss $151M.